SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) continues to experience historic, parabolic price appreciation driven by severe enterprise NAND flash shortages and aggressive institutional re-rating of the memory sector. The community remains deeply polarized, with bulls pointing to multi-year capacity constraints and essential AI infrastructure demand, while skeptics warn of extreme technical overextension and potential bubble risks.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing strong momentum driven by institutional interest following a recent price target hike and anticipation surrounding potential FDA decisions on its peptide product pipeline. The community is actively debating the stock's potential for a short squeeze, with many users focused on its ability to reclaim key moving averages while others express skepticism, comparing the current price action to previous volatility cycles.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors anticipate the imminent release of Phase 3 VELA-52 clinical trial data, which the community believes could establish the company's lead asset as the superior, best-in-class treatment for hidradenitis suppurativa. The stock is seeing significant institutional accumulation and heightened discussion regarding its potential as a prime M&A target, especially with the company's full leadership team attending the upcoming Goldman Sachs Healthcare Conference.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is trending due to strong market interest in its role as a key player in AI infrastructure, specifically regarding memory and high-performance computing demand. The community is actively discussing its potential for a significant re-rating, highlighting its partnerships with major hardware vendors and the scalability of its integrated memory solutions.

FreeCast, Inc. operates an online video streaming platform. Its cloud entertainment platform comprises the largest aggregated library of free and pay-per-view video-on-demand, streaming channels, live events, radio stations, music videos and online games. The company was founded by William A. Mobley, Jr. on June 21, 2011 and is headquartered in Orlando, FL.

Freecast Inc - Ordinary Shares - Class A

Freecast Inc

Freecast Inc. is seeing significant momentum and intense community discussion following the announcement of a reseller agreement for Starlink Business connectivity services. Traders are actively debating the stock's parabolic price action, with many focusing on potential short squeeze dynamics while others caution against the company's underlying fundamentals and the risk of dilution.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to reports of a domestic chip manufacturing partnership with Apple, a move that reinforces optimism in the company's ongoing foundry transformation. The stock is seeing significant momentum and high volume as the community actively debates whether this catalyst justifies the current valuation or represents a speculative pump.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is currently drawing significant community attention as it navigates a complex intersection of geopolitical headwinds and institutional support, specifically surrounding China's export control list and the company's critical role as a U.S. rare earth supplier. Investors are actively debating the stock's consolidation patterns near technical resistance levels, while closely monitoring how the firm's domestic magnet production and defense-linked government backing will offset macro-level uncertainty.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await a federal court decision on whether to remand the company's lawsuit against partner Nippon Shinyaku back to state court, a move seen as critical to securing independent distribution rights ahead of the expected August PDUFA date. Community focus remains locked on the potential for Deramiocel's approval to transform the standard of care for Duchenne Muscular Dystrophy, with many speculating that resolving the legal overhang will clear the path for the stock's next major leg up.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors scrutinize the heavy capital expenditure associated with AI initiatives, sparking intense debate about the stock's future compared to hardware-focused tech peers. While some market participants express frustration over prolonged technical weakness and suggest rotation into more momentum-driven sectors, others view the current valuation as an accumulation opportunity for a long-term compounder with resilient cloud growth.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is seeing significant momentum and bullish sentiment as investors eye the company's critical role in the U.S. domestic supply chain and pending government funding milestones. Community discussion is focused on the stock's potential as a long-term strategic asset, with traders closely monitoring technical breakouts and the company's positioning against competitors in the rare earth sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.read more...

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the studys dual primary endpoints, demonstrating statistically significant and clinically...

ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe

Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug...

Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present...

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com...

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the companys psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data...

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry productsLYBALVI (olanzapine and samidorphan) and ARISTADA (aripiprazole lauroxil)and its ongoing involvement in sleep medicine. The data presented...

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ALKSAlkermes plc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALKS News